Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, AUGUST 31, 2026
08:00 - 08:50
REGISTRATION AND MORNING REFRESHMENTS
08:50 - 09:00
OPENING ADDRESS
09:00 - 09:30
RESERVED PRESENTATION
09:30 - 09:55
CLEAR OR CROWDED? FTO STRATEGY FOR NEXT GENERATION ADCS
Jeffrey Morton
Haynes and Boone, LLP

Jeffrey Morton

Haynes and Boone, LLP

  • Surveying the ADC IP landscape across linker chemistry, payloads, conjugation, and target antigens
  • Conducting FTO analysis at key inflection points to prioritize freedom or design-around options
  • Navigating dominant ADC patent thickets to protect and preserve commercial freedom for developers
09:55 - 10:00
Q&A SESSION ON FTO STRATEGY AND PATENT NAVIGATION FOR ADCS
10:00 - 10:30
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:30 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON ADC
11:30 - 11:55
A NOVEL FC-OPTIMIZED ANTIBODY-DRUG CONJUGATE FOR THE THERAPY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA / T-CELL NON-HODGKIN LYMPHOMA
Matthias Peipp
University Hospital Schleswig-Holstein

Matthias Peipp

University Hospital Schleswig-Holstein

  • Presenting a novel Fc-optimized ADC for T-ALL and T-NHL with high unmet clinical need
  • Targeting a unique epitope on the antibody backbone with implications for the mode of action
  • Introducing improved Fc-mediated effector functions beyond classical ADC mechanisms
11:55 - 12:00
Q&A SESSION ON Fc-OPTIMIZED ADC THERAPY IN T-CELL MALIGNANCIES
12:00 - 12:25
ACCELERATING ADC LINKER AND PAYLOAD DESIGN THROUGH INTEGRATED COMPUTATIONAL INTELLIGENCE
Christopher Korban
Revilico

Christopher Korban

Revilico

  • Unifying generative chemistry, reinforcement learning, and physics models for ADC design
  • Simulating linker stability and payload release to validate non-obvious molecular options
  • Collapsing fragmented workflows into a closed loop that speeds smarter linker-payload choices
12:25 - 12:30
Q&A SESSION ON COMPUTATIONAL ADC LINKER DESIGN
12:30 - 13:30
NETWORKING LUNCH AND VISITING THE ADC EXHIBITION
13:30 - 14:00
PANEL DISCUSSION ON ADC
14:00 - 14:25
INTEGRATING AI-ENHANCED HISTOPATHOLOGY DATA TO OPTIMIZE ADC TARGETING IN SOLID TUMORS
Muhammad Shaiq
Precision Medicine Lab

Muhammad Shaiq

Precision Medicine Lab

  • Integrating deep learning with histopathology to map antigen patterns for sharper ADC selection
  • Analyzing tumor microenvironments with computational models to predict barriers to ADC entry
  • Correlating imaging data with payload choice to detect and overcome early ADC resistance
14:25 - 14:30
Q&A SESSION ON AI-ENHANCED ADC TARGETING IN SOLID TUMORS
14:30 - 14:55
PATIENT DECISION DATA ON ADC ADOPTION, EYE TOXICITY, AND TREATMENT TIMING
Jay Hydren
HealthTree Foundation

Jay Hydren

HealthTree Foundation

  • Revealing strong polarization in ADC preference driven by how eye toxicity is described
  • Examining how prior CAR-T and bispecific exposure shifts patients away from later ADC use
  • Clarifying which communication, support, and timing factors may reshape ADC decisions
14:55 - 15:00
Q&A SESSION ON ADC PERCEPTION, TOXICITY, AND TIMING
15:00 - 15:20
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:20 - 15:50
PANEL DISCUSSION ON ADC
15:50 - 16:15
AIDD-DIRECTED DISCOVERY OF NON-CPT TOPO1 INHIBITOR PAYLOADS TO ADDRESS DXD-ADC RESISTANCE
Qun Dang
Genuine Biotech

Qun Dang

Genuine Biotech

  • Applying AIDD to find non-CPT Topo1 payloads that overcome resistance to DXD and SN-38
  • Preserving single-digit nanomolar potency against wild type and R364H mutant Topo1 enzyme
  • Demonstrating broad tumor inhibition with stronger activity than irinotecan in models tested
16:15 - 16:20
Q&A SESSION ON NON-CPT TOPO1 PAYLOADS FOR ADC RESISTANCE
16:20 - 16:45
TARGETING WHAT REMAINS: THE NON-SHED MUC1-C SUBUNIT UNLOCKS SUPERIOR ADC TARGETING IN SOLID TUMORS
Ravi Jasuja
XYone Therapeutics

Ravi Jasuja

XYone Therapeutics

  • Leveraging non-shed MUC1-C to avoid variable targeting caused by shed MUC1-N in tumors
  • Comparing MUC1-C with DS-3939a DXd to show stronger occupancy and internalization
  • Enabling stable antigen engagement across multispecific antibody formats and designs
  • Delivering potent anti-tumor activity with durable effects and favorable preclinical safety
16:45 - 16:50
Q&A SESSION ON ADC TARGETING IN SOLID TUMORS
16:50 - 17:15
DESIGNING ADCS FOR GLOBAL SUCCESS: ALIGNING CLINICAL STRATEGY WITH REGULATORY AND MARKET REALITIES
Balal Mian
Aurelian Life Sciences

Balal Mian

Aurelian Life Sciences

  • Structuring ADC programs with the end market in mind to drive global regulatory and commercial success
  • Prioritizing tumor types and biomarker strategies for scientific rationale and trial efficiency
  • Supporting parallel regulatory pathways through simultaneous multi-region clinical data generation
  • Embedding mitigation early by addressing ADC-specific safety, manufacturability, and dosing hurdles
17:15 - 17:20
Q&A SESSION ON ADC GLOBAL REGULATORY AND CLINICAL STRATEGY
17:20 - 18:20
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, SEPTEMBER 1, 2026
08:00 - 08:30
MORNING REFRESHMENTS
08:30 - 08:40
OPENING ADDRESS
08:40 - 09:10
PANEL DISCUSSION ON ADC
09:10 - 09:35
NANOFITIN-DRUG CONJUGATES : SMALL FORMATS FOR IN-AND-OUT TARGETED THERAPIES AGAINST SOLID TUMOURS
Olivier Kitten
Affilogic

Olivier Kitten

Affilogic

  • Utilizing 7 kDa Nanofitin scaffolds with tuned affinity to drive rapid and selective tumor penetration
  • Concentrating toxic drug delivery within tumor volume while limiting off-tumor targeting effects
  • Showcasing durable tumor regression in animal models with fast-acting and focused efficacy
09:35 - 09:40
Q&A SESSION ON NANOFITIN-DRUG CONJUGATES IN SOLID TUMORS
09:40 - 10:05
DEVELOPMENT OF A FIRST-IN-CLASS OX40-ADC FOR THE TREATMENT OF LYMPHOMA
Henry Li
Hanx Biopharmaceuticals, Inc.

Henry Li

Hanx Biopharmaceuticals, Inc.

  • Establishing OX40 as a novel TAA in lymphoma subtypes based on molecular epidemiology
  • Discovering a non-blocking OX40 antibody with exceptionally high internalization capacity
  • Creating an OX40-ADC for OX40-positive lymphoma with preclinical and clinical perspectives
10:05 - 10:10
Q&A SESSION ON FIRST-IN-CLASS OX40-ADC IN LYMPHOMA
10:10 - 10:30
MORNING COFFEE BREAK IN THE EXHIBIT AREA
10:30 - 10:55
AI-DRIVEN SPATIAL HISTOPATHOLOGY FOR MULTISPECIFIC ADCS
Patrick Savickas
HistoWiz

Patrick Savickas

HistoWiz

  • Automating GLP-compliant spatial histopathology to quantify antigen distribution and ADC trafficking
  • Deploying mIF and AI image analysis to predict off-target toxicity and optimize therapeutic index
  • Validating multispecific ADC efficacy in complex tumor microenvironments to address resistance
10:55 - 11:00
Q&A SESSION ON SPATIAL HISTOPATHOLOGY FOR MULTISPECIFIC ADCS
11:00 - 11:25
FEASIBLE STANDARDIZATION FOR OMIC-LEVEL FLOW CYTOMETRY BIOMARKER DISCOVERY
Matthew Kunicki
Interro IQ

Matthew Kunicki

Interro IQ

  • Achieving end-to-end wet- and dry-lab rigor to support omic-level standardization in flow cytometry
  • Designing panels around clinically relevant cell populations to reduce ambiguity in high-dimensional data
  • Translating flow cytometry discoveries rapidly from research settings into clinical applications
11:25 - 11:30
Q&A SESSION ON FLOW CYTOMETRY BIOMARKER STANDARDIZATION
11:30 - 11:55
TRIVALENT-IG SCAFFOLDS FOR PAN-NKG2DL TARGETING AND INTERNALIZATION
David Meininger
SovranBio

David Meininger

SovranBio

  • Framing trivalent-Ig scaffolds that expand mono-, bi-, and trispecific antibody design
  • Resolving light-chain pairing challenges while preserving aligned paratopes for binding
  • Demonstrating pan-NKG2DL binding and internalization to strengthen tumor targeting
  • Positioning a lead program for 2027 IND while advancing broader scaffold validation
11:55 - 12:00
Q&A SESSION ON PAN-NKG2DL TRIVALENT-IG SCAFFOLDS
12:00 - 12:15
FEEDBACK AND RAFFLE DRAW
12:15 - 12:30
CLOSING REMARKS
12:30 - 13:30
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.